208 related articles for article (PubMed ID: 22399516)
41. Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study.
Tehrani DM; Gardin JM; Yanez D; Hirsch CH; Lloyd-Jones DM; Stein PK; Wong ND
Atherosclerosis; 2013 Dec; 231(2):246-51. PubMed ID: 24267235
[TBL] [Abstract][Full Text] [Related]
42. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile.
Dullaart RP; Constantinides A; Perton FG; van Leeuwen JJ; van Pelt JL; de Vries R; van Tol A
J Clin Endocrinol Metab; 2011 Apr; 96(4):1077-84. PubMed ID: 21252249
[TBL] [Abstract][Full Text] [Related]
43. Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosis.
Kinney GL; Snell-Bergeon JK; Maahs DM; Eckel RH; Ehrlich J; Rewers M; Hokanson JE
Diabetes Technol Ther; 2011 Mar; 13(3):381-7. PubMed ID: 21291330
[TBL] [Abstract][Full Text] [Related]
44. Lp-PLA
Siddiqui MK; Kennedy G; Carr F; Doney ASF; Pearson ER; Morris AD; Johnson T; McLaughlin MM; Williams RE; Palmer CNA
Diabetologia; 2018 Jun; 61(6):1344-1353. PubMed ID: 29623345
[TBL] [Abstract][Full Text] [Related]
45. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.
Hatoum IJ; Hu FB; Nelson JJ; Rimm EB
Diabetes; 2010 May; 59(5):1239-43. PubMed ID: 20185811
[TBL] [Abstract][Full Text] [Related]
46. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
; Thompson A; Gao P; Orfei L; Watson S; Di Angelantonio E; Kaptoge S; Ballantyne C; Cannon CP; Criqui M; Cushman M; Hofman A; Packard C; Thompson SG; Collins R; Danesh J
Lancet; 2010 May; 375(9725):1536-44. PubMed ID: 20435228
[TBL] [Abstract][Full Text] [Related]
47. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.
Gregson J; Stirnadel-Farrant HA; Doobaree IU; Koro C
Atherosclerosis; 2012 Nov; 225(1):11-21. PubMed ID: 22784637
[TBL] [Abstract][Full Text] [Related]
48. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians.
Anuurad E; Ozturk Z; Enkhmaa B; Pearson TA; Berglund L
J Clin Endocrinol Metab; 2010 May; 95(5):2376-83. PubMed ID: 20194707
[TBL] [Abstract][Full Text] [Related]
49. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.
Madjid M; Ali M; Willerson JT
Tex Heart Inst J; 2010; 37(1):25-39. PubMed ID: 20200624
[TBL] [Abstract][Full Text] [Related]
50. Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Wang C; Fang X; Hua Y; Liu Y; Zhang Z; Gu X; Wu X; Tang Z; Guan S; Liu H; Liu B; Guo X; Ji X
Angiology; 2018 Jan; 69(1):49-58. PubMed ID: 28429599
[TBL] [Abstract][Full Text] [Related]
51. Racial variation in lipoprotein-associated phospholipase A₂ in older adults.
Lee KK; Fortmann SP; Varady A; Fair JM; Go AS; Quertermous T; Hlatky MA; Iribarren C
BMC Cardiovasc Disord; 2011 Jun; 11():38. PubMed ID: 21714927
[TBL] [Abstract][Full Text] [Related]
52. Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome.
Xu C; Yu F; Mao S; Shi Y; Li Q; Fang S; Tan Y; Gu W; Ye L
Respir Med; 2020 Mar; 163():105881. PubMed ID: 32056835
[TBL] [Abstract][Full Text] [Related]
53. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.
Blake GJ; Dada N; Fox JC; Manson JE; Ridker PM
J Am Coll Cardiol; 2001 Nov; 38(5):1302-6. PubMed ID: 11691499
[TBL] [Abstract][Full Text] [Related]
54. Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.
Schnabel R; Dupuis J; Larson MG; Lunetta KL; Robins SJ; Zhu Y; Rong J; Yin X; Stirnadel HA; Nelson JJ; Wilson PW; Keaney JF; Vasan RS; Benjamin EJ
Atherosclerosis; 2009 Jun; 204(2):601-7. PubMed ID: 19135199
[TBL] [Abstract][Full Text] [Related]
55. Role of vitamin D in risk factors of patients with type 2 diabetes mellitus.
Zhang Q; Wu Y; Lu Y; Fei X
Med Clin (Barc); 2020 Mar; 154(5):151-156. PubMed ID: 31255367
[TBL] [Abstract][Full Text] [Related]
56. Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults.
Olson N; O'Meara ES; Jenny NS; Folsom AR; Bovill EG; Furberg CD; Heckbert SR; Psaty BM; Cushman M
Am J Hematol; 2008 Jul; 83(7):524-7. PubMed ID: 18383322
[TBL] [Abstract][Full Text] [Related]
57. The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.
Allison MA; Denenberg JO; Nelson JJ; Natarajan L; Criqui MH
J Vasc Surg; 2007 Sep; 46(3):500-6. PubMed ID: 17681710
[TBL] [Abstract][Full Text] [Related]
58. Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study.
Folsom AR; Lutsey PL; Roetker NS; Ballantyne CM; Hoogeveen RC; Rosamond WD; Cushman M;
Thromb Res; 2013 Jul; 132(1):44-6. PubMed ID: 23746626
[TBL] [Abstract][Full Text] [Related]
59. Association of lipoprotein-associated phospholipase A
Garg PK; Bartz TM; Norby FL; Jorgensen NW; McClelland RL; Ballantyne CM; Chen LY; Gottdiener JS; Greenland P; Hoogeveen R; Jenny NS; Kizer JR; Rosenson RS; Soliman EZ; Cushman M; Alonso A; Heckbert SR
Am Heart J; 2018 Mar; 197():62-69. PubMed ID: 29447785
[TBL] [Abstract][Full Text] [Related]
60. Diurnal variation in lipoprotein-associated phospholipase A(2) (Lp-PLA(2)).
Kaminsky LA; Ozemek C
Clin Biochem; 2012 Jun; 45(9):700-2. PubMed ID: 22465237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
